Dexcom, Inc.
Thesis
Dexcom is facing significant challenges due to increasing competition from integrated devices that combine continuous glucose monitoring (CGM) technology with insulin pump therapy. The company's revenue growth is under pressure as customer acquisition costs rise and the market is not valuing the business based on earnings or cash flow, but rather on market opportunity. With the potential for pricing pressure and a saturated market, the stock is expected to decline.
Did it work?
Without specific price performance data or a defined time frame since the pitch, it's difficult to assess whether the thesis has played out. The thesis highlights significant competitive challenges and market dynamics, but without evidence of stock price movement or confirmation of these factors, the outcome remains uncertain.
Raw excerpt
No raw excerpt stored.